COMBINATION

1 . A combination comprising:

(i) a first compound of Structure (I):

or a pharmaceutically acceptable salt or solvate thereof; and

(ii) a second compound which is a compound of Structure (II)

or a pharmaceutically acceptable salt thereof.

2 . A combination according to claim 1 where the compound of Structure (I) is in the form of a methanesulfonate salt and the compound of Structure (II) is in the form of a free base.

3 . A combination kit comprising a combination according to claim 1 together with a pharmaceutically acceptable carrier or carriers.

4 . A combination according to claim 1 where the amount of the compound of Structure (I) is an amount selected from 10 mg to 300 mg, and that amount is administered from 1 to 4 times per day, and the amount of the compound of Structure (II) is an amount selected from 0.5 mg to 20 mg, and that amount is administered once per day.

5 . A combination kit comprising a combination according to claim 1 together with a pharmaceutically acceptable carrier or carriers.

6 . A method of treating cancer in a human in need thereof which comprises the in vivo administration of a therapeutically effective amount of a combination of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof and 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, to such human,

wherein the combination is administered within a specified period, and

wherein the combination is administered for a duration of time.

7 . A method of claim 6 , which comprises the in vivo administration of a therapeutically effective amount of a combination of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate salt and 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, to such human,

wherein the combination is administered within a specified period, and

wherein the combination is administered for a duration of time.

8 . A method according to claim 6 wherein the amount of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, is selected from about 10 mg to about 300 mg, and that amount is administered from 1 to 3 times per day, and the amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide is selected from about 0.5 mg to about 10 mg.

9 . A method according to claim 6 wherein the amount of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, is selected from about 70 mg to about 260 mg, and that amount is administered twice per day, and the amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide is selected from about 0.5 mg to about 6 mg

10 . A method according to claim 8 wherein N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide are administered within 12 hours of each other each day for a period of at least 7 consecutive days, optionally followed by one of more repeating cycles.

11 . A method according to claim 6 wherein N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate salt and the amount of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide are administered within 12 hours of each other each day for a period of at least 14 consecutive days, optionally followed by one of more repeating cycles.

12 . A method of treating cancer in a human in need thereof which comprises one or more dosing cycles, wherein each said cycle comprises (1) administering to the human from about 10 to 300 mg of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt or solvate thereof, 1-4 times a day for 1-30 days; and (2) periodically administering to the human from about 0.05 mg to 10 mg of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt or solvate.

13 . (canceled)

14 . A method of treating cancer in a human in need thereof which comprises one or more dosing cycles, wherein each said cycle comprises (1) administering to the human from about 0.05 to 10 mg of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt or solvate thereof, once or twice a day for 1-30 days; and (2) periodically administering to the human from about 10 to 300 mg of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt or solvate thereof for 1-30 days.

15 . (canceled)

16 . A method of claim 12 , wherein 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide is administered, once every 2-4 days.

17 . A method of claim 12 , wherein 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide is administered, once every 5-7 days.

18 . A method of claim 12 , wherein 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide is administered, once every 8-15 days.

19 . A method of claim 14 , wherein N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate is administered, once every 2-4 days.

20 . A method of claim 14 , wherein N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate is administered once every 5-7 days.

21 . A method of claim 14 , wherein N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide methanesulfonate is administered once every 8-15 days.

22 . A method of treating cancer in a human in need thereof which comprises one or more repeating dosing cycles, wherein each said cycle comprises administering to the human from about 10 to 300 mg of N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt or solvate thereof, 1-4 times a day for 5-14 days, followed by administering to the human from about 0.05 mg to 10 mg of 2,4-difluoro-N-{2-(methyloxy)-5-[4-(4-pyridazinyl)-6-quinolinyl]-3-pyridinyl}benzenesulfonamide, or a pharmaceutically acceptable salt or solvate for 5-14 days.

23 . (canceled)

24 . A method according to claim 12 , wherein said cancer is melanoma or colon.

25 . (canceled)

26 . A combination according to claim 1 wherein said second compound is in the form of free base.

27 .- 30 . (canceled)

31 . A method of claim 8 , wherein said cancer is melanoma, lung, pancreatic, breast or colon.

32 .- 33 . (canceled)

34 . A method according to claim 12 , wherein said cancer is melanoma which has progressed after being treated with a BRaf inhibitor.

35 . (canceled)

36 . A method according to claim 12 , wherein said cancer is colon cancer which has progressed after being treated with a BRaf inhibitor.

37 . (canceled)